Your session is about to expire
← Back to Search
Ovarian Function Suppression + Aromatase Inhibitor for Breast Cancer(OFSET Trial)
OFSET Trial Summary
This trial will test if adding chemotherapy to hormones improves the likelihood of survival from early stage ER+ breast cancer. #breastcancer #chemotherapy #hormones
- Breast Cancer
OFSET Trial Eligibility Criteria
Inclusion CriteriaYou will be eligible if you check “Yes” for the criteria below
OFSET Trial Timeline
Study ObjectivesOutcome measures can provide a clearer picture of what you can expect from a treatment.
Awards & Highlights
OFSET Trial Design
Find a Location
Who is running the clinical trial?
Frequently Asked Questions
Has the Federal Drug Administration sanctioned Arm 1: Ovarian Function Suppression + Aromatase Inhibitor?
"Our internal analysis at Power scored Arm 1: Ovarian Function Suppression + Aromatase Inhibitor with a 3 due to the Phase 3 clinical trial that provided evidence of its efficacy and safety."
What is the current total of participants in this research project?
"That is correct. Clinicaltrials.gov states that this research project, which was first available on August 31st 2023, is currently recruiting participants from one site in need of 3960 volunteers."
Can individuals below the age of 45 partake in this research project?
"As stipulated in the study's conditions, only individuals aged 18-60 may take part."
Am I able to register for participation in this clinical study?
"To be eligible for the study, candidates must have a diagnosis of breast cancer and fall between 18 to 60 years old. The research team is aiming to recruit 3960 volunteers in total."
Is the call for participants still open on this particular clinical trial?
"Affirmative. As indicated by the data available on clinicaltrials.gov, this medical research study is currently recruiting subjects and was most recently updated in August of 2023. The trial requires 3960 patients to be recruited from one location."
Share this study with friends